Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2024-08-25 Interim / Quarterly Rep…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
2024年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "半年度报告 2024" which translates to "2024 Semi-Annual Report." It contains detailed financial data including income, profit, assets, liabilities, and operational analysis for the period January 1, 2024 to June 30, 2024. The document includes sections such as company overview, accounting data, business conditions, financial statements, and risk disclosures. It explicitly states it is a half-year report and contains comprehensive financial statements and analysis, not just an announcement or summary. The length is substantial (15,000 characters), and it is not a certification or a brief announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2024
2024-08-25 Chinese
关于使用部分闲置募集资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about the authorized entrusted financial management, the types and amounts of financial products purchased, risk control measures, and detailed tables of ongoing and matured entrusted financial products. The content focuses on the company's use of idle raised funds for short-term financial investments, with no indication of it being a full financial report, earnings release, or management discussion. It is a regulatory disclosure about capital usage and investment activities related to fundraising proceeds. This fits best under the category of Capital/Financing Update (CAP), as it updates on the company's financing activities and use of raised capital funds.
2024-08-18 Chinese
2024年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a formal announcement of the resolutions passed at the 2024 second extraordinary general meeting of shareholders of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions confirming the validity of the meeting and resolutions. The content focuses on shareholder meeting decisions and voting outcomes rather than presenting a full report or financial statements. The document length is relatively short (1659 characters) and it is clearly an official announcement of voting results from a shareholders' meeting. Therefore, it fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2024-08-11 Chinese
上海天璇律师事务所关于四川梓橦宫药业股份有限公司2024年第二次临时股东大会的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the procedural legality of the 2024 second extraordinary shareholders' meeting of Sichuan Zitonggong Pharmaceutical Co., Ltd. It details the convening, attendance, voting procedures, and results of the shareholders' meeting, confirming compliance with relevant laws and company articles. It does not contain financial statements, earnings data, or management discussion but focuses on the legal validation of the shareholders' meeting process and voting results. This type of document is a legal proceedings report related to corporate governance and shareholder meetings, fitting the category of Legal Proceedings Report (LTR). The document length is 3009 characters, which is substantive and not a mere announcement or certification, supporting this classification.
2024-08-11 Chinese
关于使用自有闲置资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using its own idle funds to purchase financial products. It includes extensive information about the amounts, types, terms, and counterparties of various entrusted financial products, as well as risk control measures and disclosures in compliance with the Beijing Stock Exchange listing rules. The document is a regulatory disclosure about financing activities related to the company's capital management, specifically the use of idle funds for investment in low-risk financial products. It is not a full financial report, earnings release, or management discussion, nor is it a voting result or board change announcement. The content fits best under the category of Capital/Financing Update (CAP) as it updates on the company's financing activities and capital usage. The document length is substantial and contains detailed financial data about the entrusted financial products, supporting a confident classification.
2024-08-11 Chinese
关于使用部分闲置募集资金委托理财进展的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the progress of using part of idle raised funds to purchase financial products. It includes specifics about the authorized entrusted financial management, the types and amounts of financial products purchased, risk control measures, and a risk warning. The document is not a financial report like an annual or interim report, nor is it a call transcript or management report. It is a regulatory disclosure about the company's capital management activities, specifically the use of idle raised funds for entrusted financial management. It does not announce voting results, board changes, or dividends. The document is comprehensive and exceeds 5,000 characters, so it is not merely a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it updates on the company's financing activities related to the use of raised funds for financial products.
2024-08-11 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.